Damaged cardiac tissue

Damaged cardiac tissue refers to myocardium that has undergone pathological changes, such as necrosis, apoptosis, or fibrosis, typically resulting from ischemia, inflammation, or chronic hemodynamic stress [5, 8]. This condition is a hallmark of cardiovascular diseases like myocardial infarction and heart failure, where the loss of functional cardiomyocytes leads to impaired pump function and adverse ventricular remodeling [7, 12]. While not a single molecular entity, damaged cardiac tissue is a primary focus for therapeutic strategies ranging from traditional pharmacological management, such as ACE inhibitors and beta-blockers, to advanced regenerative medicine, including stem cell therapy and targeted drug delivery systems [1, 11]. These interventions aim to preserve existing tissue, promote the repair of injured cells, or replace lost myocardium with functional tissue to restore cardiac output and improve patient outcomes [3, 10]. The microenvironment of the damaged tissue, characterized by inflammation and altered extracellular matrix, presents both a challenge and an opportunity for targeted drug delivery systems designed to restore cardiac function [7, 11].

Other names

Myocardial injuryInfarcted myocardiumCardiac scar tissueIschemic heart tissueDiseased cardiac tissue

Therapeutic strategies for damaged cardiac tissue include reducing myocardial workload, inhibiting the renin-angiotensin-aldosterone system to prevent adverse remodeling, promoting angiogenesis via growth factor delivery, and attempting to stimulate cardiomyocyte regeneration or replacement through cell-based or genetic therapies [5, 7, 8, 10].